EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY 4.0

Pituitary neuroendocrine tumors with PIT1/SF1 co-expression show distinct clinicopathological and molecular features

Matthias Dottermusch iD, Alice Ryba, Franz L Ricklefs, Jörg Flitsch, Simone Schmid, Markus Glatzel, Wolfgang Saeger, Julia E Neumann, Ulrich Schüller iD

Acta Neuropathologica · 2024

DOI: 10.1007/s00401-024-02686-1 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Acta Neuropathologica, 2024. Verfasst von Matthias Dottermusch und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany. m.dottermusch@uke.de. Hauptthemen laut MEDLINE: Adenoma, Neuroendocrine Tumors, Pituitary Neoplasms. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CSRD VA, Fördergemeinschaft Kinderkrebs-Zentrum Hamburg, Universitätsklinikum Hamburg-Eppendorf (UKE).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pituitary neuroendocrine tumors (PitNETs) are classified according to cell lineage, which requires immunohistochemistry for adenohypophyseal hormones and the transcription factors (TFs) PIT1, SF1, and TPIT. According to the current WHO 2022 classification, PitNETs with co-expression of multiple TFs are termed “plurihormonal”. Previously, PIT1/SF1 co-expression was prevailingly reported in PitNETs, which otherwise correspond to the somatotroph lineage. However, little is known about such tumors and the WHO classification has not recognized their significance. We compiled an in-house case series of 100 tumors, previously diagnosed as somatotroph PitNETs. Following TF staining, histopathological features associated with PIT1/SF1 co-expression were assessed. Integration of in-house and publicly available sample data allowed for a meta-analysis of SF1-associated clinicopathological and molecular features across a total of 270 somatotroph PitNETs. The majority (74%, 52/70) of our densely granulated somatotroph PitNETs (DGST) unequivocally co-expressed PIT1 and SF1 (DGST-PIT1/SF1). None (0%, 0/30) of our sparsely granulated somatotroph PitNETs (SGST) stained positive for SF1 (SGST-PIT1). Among DGST, PIT1/SF1 co-expression was significantly associated with scarce FSH/LH expression and fewer fibrous bodies compared to DGST-PIT1. Integrated molecular analyses including publicly available samples confirmed that DGST-PIT1/SF1, DGST-PIT1 and SGST-PIT1 represent distinct tumor subtypes. Clinicopathological meta-analyses indicated that DGST-PIT1 respond more favorably towards treatment with somatostatin analogs compared to DGST-PIT1/SF1, while both these subtypes show an overall less aggressive clinical course than SGST-PIT1. In this study, we spotlight that DGST with co-expression of PIT1 and SF1 represent a common, yet underrecognized, distinct PitNET subtype. Our study questions the rationale of generally classifying such tumors as “plurihormonal”, and calls for a refinement of the WHO classification. We propose the term “somatogonadotroph PitNET”.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenomaNeuroendocrine TumorsPituitary NeoplasmsHumansCell LineageTranscription FactorsSteroidogenic Factor 1Transcription Factor Pit-1

Stichwörter der Autor:innen

MethylationMultilineagePIT1PitNETPituitarySF1

Substanzen

Transcription FactorsSteroidogenic Factor 1POU1F1 protein, humanTranscription Factor Pit-1NR5A1 protein, human

Autor:innen und Institutionen

  • Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany. m.dottermusch@uke.de.
  • Center for Molecular Neurobiology (ZMNH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany. m.dottermusch@uke.de.
  • Department of Neurosurgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Department of Neuropathology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany.
  • Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

ORCID-Profile: Matthias Dottermusch, Ulrich Schüller

Förderung

  • CSRD VA
  • Fördergemeinschaft Kinderkrebs-Zentrum Hamburg
  • Universitätsklinikum Hamburg-Eppendorf (UKE)

Zitieren

APA

Dottermusch, M., Ryba, A., Ricklefs, F. L., Flitsch, J., Schmid, S., Glatzel, M., Saeger, W., Neumann, J. E., & Schüller, U. (2024). Pituitary neuroendocrine tumors with PIT1/SF1 co-expression show distinct clinicopathological and molecular features. Acta Neuropathologica. https://doi.org/10.1007/s00401-024-02686-1

Vancouver

Dottermusch M, Ryba A, Ricklefs FL, Flitsch J, Schmid S, Glatzel M, et al. Pituitary neuroendocrine tumors with PIT1/SF1 co-expression show distinct clinicopathological and molecular features. Acta Neuropathologica. 2024. doi:10.1007/s00401-024-02686-1

BibTeX
@article{Dottermusch2024,
  author = {Dottermusch, Matthias and Ryba, Alice and Ricklefs, Franz L and Flitsch, Jörg and Schmid, Simone and Glatzel, Markus and Saeger, Wolfgang and Neumann, Julia E and Schüller, Ulrich},
  title = {Pituitary neuroendocrine tumors with PIT1/SF1 co-expression show distinct clinicopathological and molecular features},
  journal = {Acta Neuropathologica},
  year = {2024},
  doi = {10.1007/s00401-024-02686-1}
}
Kostenlos starten →